SAM
VRDN icon

SEB Asset Management’s Viridian Therapeutics VRDN Stock Holding History

SEB Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156,957
Closed -$3.07M – 734
2026
Q1 		$3.07M Buy
+156,957
New +$4.66M 0.01% 530

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SEB Asset Management's VRDN Position: Q2 2026 in Review

SEB Asset Management sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 156,957 shares — an estimated $3.07M sold.

SEB Asset Management first reported a position in VRDN in Q1 2026 and held it in 1 quarter. The position peaked at $3.07M in Q1 2026. 193 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • SEB Asset Management reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SEB Asset Management sold 156,957 Viridian Therapeutics shares in Q2 2026, an estimated $3.07M.
  • SEB Asset Management first reported a position in Viridian Therapeutics in Q1 2026 and held it in 1 quarter.
  • SEB Asset Management's Viridian Therapeutics position peaked at $3.07M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.